Drug name | Number of trials | Pharmaceutical company | Type of cancer | Trial name available |
---|---|---|---|---|
Afatinib | 6 | Boehringer Ingelheim | Head and neck squamous cell carcinoma, non-small cell lung cancer | LUX-Head and Neck 1, LUX-Lung 5, LUX-Lung 6, LUX-Lung 8, LUX-LUNG 1 |
Bevacizumab | 6 | Roche | Non-small cell lung cancer | ATLAS, EURTAC, BeTa |
Cabozantinib | 4 | Exelixis | Medullary thyroid cancer, renal cell carcinoma, prostate cancer | EXAM, METEOR, COMET-1, COMET-2 |
Cediranib | 5 | AstraZeneca | Ovarian cancer, colorectal cancer, renal cell carcinoma, glioblastoma | ICON6, HORIZON III, HORIZON II, REGAL |
Cediranib | 2 | NCIC Clinical Trials Group | Non-small cell lung cancer | |
Erlotinib | 1 | Roche | Non-small cell lung cancer | |
Everolimus | 1 | Novartis | Neuro-endocrine tumour (gastro-intestinal or lung origin) | RADIANT-4 |
Lenvatinib | 4 | Eisai | Non-small cell lung cancer, glioma, differentiated thyroid cancer, hepatocellular carcinoma | SELECT |
Nivolumab | 4 | Bristol-Myers Squibb | Renal cell carcinoma, non-small cell lung cancer, melanoma | CheckMate 025, CheckMate 057, CheckMate 067, Checkmate 069 |
Olaratumab | 3 | ImClone Systems | Ovarian cancer, non-small cell lung cancer, prostate cancer | |
Palbociclib | 3 | Pfizer | Breast cancer | PALOMA-2, PALOMA-3, PALOMA-4 |
Pembrolizumab | 3 | Merck | Melanoma, non-small cell lung cancer | Keynote-006, Keynote-010, Keynote-024 |